Monovisc Approval History
Monovisc (sodium hyaluronate) is a viscoelastic supplement indicated for the treatment of pain associated with osteoarthritis of the knee.
Development History and FDA Approval Process for Monovisc
|Feb 27, 2014||FDA Approves Monovisc, a New Single Injection Treatment for Pain Due to Osteoarthritis of the Knee|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.